54052-62-9

Usage

Uses

Used in Pharmaceutical Synthesis:
2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(2-methylpropyl)is used as a key intermediate in the synthesis of pharmaceuticals for its unique structural features and potential to form new drug molecules. The presence of the 2-methylpropyl group and amino groups allows for the creation of various chemical bonds and interactions, which can be exploited in the development of new therapeutic agents.
Used in Medicinal Chemistry Research:
2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(2-methylpropyl)is used as a research compound in medicinal chemistry to explore its potential as a precursor for the development of new drugs. 2,4(1H,3H)-Pyrimidinedione, 5,6-diamino-1-(2-methylpropyl)-'s unique structure and properties make it a valuable tool for studying the interactions between molecules and their biological targets, which can lead to the discovery of novel therapeutic agents.

Upstream product

• 54052-65-2 1-isobutyl-5-nitroso-6-amino uracil 
• 56075-75-3 6-amino-1-isobutyl-1,3-dihydropyrimidine-2,4-dione 

Downstream Products

• 480445-50-9 N-(6-amino-1-isobutyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-2-(4-bromo-phenyl)-acetamide 
• 63908-37-2 3-Isobutyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin 
• 75914-95-3 3,7-dihydro-8-methyl-3-(2-methylpropyl)-1H-purine-2,6-dione 
• 110480-48-3 3-isobutyl-8-[2-(4-diphenylmethylpiperazinyl)ethyl]xanthine 
• 480445-51-0 8-(4-bromo-benzyl)-3-isobutyl-3,7-dihydro-purine-2,6-dione 

Relevant academic research and scientific papers

Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A2B AdoR (Ki = 6 nM and 7 nM, respectively) and greater selectivity for the human A1, A2A, and A3 AdoRs (>1000-, >830-, and >1500-fold; >850-, >700-, and >1280-fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A2B AdoR.

XANTHINE DERIVATIVES AS A2B ADENOSINE RECEPTOR ANTAGONISTS

Disclosed are compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

A2B adenosine receptor antagonists

Disclosed are novel compounds that are A2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

A solid-phase approach towards the synthesis of PDE5 inhibitors.

PDE5 inhibitors based upon the xanthine scaffold 8 have been expediently synthesized using a solid-phase route. Attachment of the xanthine scaffold 8 using the Rink chloride linker 4 and N-1 functionalization using Mitsunobu chemistry is described. A library of compounds was produced in multi-milligram quantities with excellent purities and acceptable yields. The compounds were tested for their PDE5 inhibitory activity.

Substituted xanthines, pteridinediones, and related compounds as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor α

A series of analogues of pentoxifylline metabolites were prepared in the purine, pteridine, [1,2,5]-thiadiazolo[3,4-d]pyrimidine, and quinazoline ring systems and evaluated for their ability to inhibit the production of tumor necrosis factor-α (TNFα) in human peripheral blood monocytes stimulated with bacterial lipopolysaccharide (LPS). The more active compounds were also tested for inhibition of cyclic AMP phosphodiesterase type IV (PDE IV) from human neutrophils in order to help determine their mechanism of action. Selected compounds which showed good activity in the in vitro TNFα assay were evaluated in an in vivo LPS-induced leukopenia model in mice. The most potent compounds in the TNFα assay, 6, 31, and 58, inhibited TNFα production at an IC50 of approximately 5 μM for each. Compound 58 was a very poor inhibitor of PDE IV but was the most active at preventing the leukopenia induced by TNFα in mice, providing more than 60% protection at 50 mg/kg. Thus, compounds such as 58, which are good inhibitors of TNFα production but are devoid of PDE IV inhibitory properties, may have potential as new antiinflammatory agents.

New xanthine derivatives with potent and long lasting anti-bronchoconstrictive activity

Twenty eight new derivatives of 8-aminoalkyl substituted xanthine have been synthesized.They all have demonstrated a potent anti-bronchoconstrictive effect in the guinea pig and some of them have a very long duration of action (>48 h).Among them, one compound: 1-methyl 3-isobutyl 8-(4-benzhydryl piperazino ethyl)xanthine (57) (S 9795) has been selected for clinical trials in asthmatic patients because of its long duration of action, its lack of CNS stimulating effects and its inhibiting action on mast cell degranulation and phosphodiesterase activity.Keywords - 8-aminoalkyl substituted xanthines / benzhydryl piperazine / piperidine / ethylenediamine / anti-bronchoconstrictors / phosphodiesterase inhibitors / asthma